<DOC>
	<DOCNO>NCT01797718</DOCNO>
	<brief_summary>Boys constitutional delay growth puberty ( CDGP ) offer evidence-based effective safe treatment option . This study compare effect low-dose testosterone aromatase inhibitor letrozole pubertal progression . The hypothesis , boys CDGP show early sign puberty , peroral letrozole ( 2.5 mg/d 6 mo ) induce faster biochemical clinical progression puberty compare low-dose intramuscular testosterone Rx ( ~1mg/kg/mo 6 mo ) . In addition , 10 boy select watchful wait instead medication provide background data natural progression CDGP , data use primary statistical comparison .</brief_summary>
	<brief_title>Constitutional Delay Growth Puberty : Towards Evidence-based Treatment</brief_title>
	<detailed_description />
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Constitutional delay growth puberty Age 14 year mean testicular volume 2.5 ml less 4 ml serum testosterone level le 5 nM OR , serum testosterone 1 nM normal DHEAS level , even mean testicular volume le 2.5 ml OR , tanner stage G2 testosterone level le 3 nM Chronic disease Primary secondary hypogonadism Chromosomal anomalies Chronic medication potentially adversely affect bone mineralization ( exclude inhale corticosteroid treatment )</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Puberty</keyword>
	<keyword>Constitutional</keyword>
	<keyword>Delay</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Testosterone</keyword>
</DOC>